MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy

Kjersti Skipar; Tord Hompland; Kjersti V Lund; Kristina Lindemann; Taran P Hellebust; Kjersti Bruheim; Heidi Lyng

doi:10.1016/j.radonc.2024.110263

MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy

Radiother Oncol. 2024 Mar 29:195:110263. doi: 10.1016/j.radonc.2024.110263. Online ahead of print.

Authors

Kjersti Skipar¹, Tord Hompland², Kjersti V Lund³, Kristina Lindemann⁴, Taran P Hellebust⁵, Kjersti Bruheim⁶, Heidi Lyng⁷

Affiliations

¹ Department of Radiation Biology, Oslo University Hospital, Oslo, Norway; Department of Oncology, Telemark Hospital Trust, Skien, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
² Department of Radiation Biology, Oslo University Hospital, Oslo, Norway.
³ Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
⁴ Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Gynecological Oncology, Oslo University Hospital, Oslo, Norway.
⁵ Department of Medical Physics, Oslo University Hospital, Oslo, Norway.
⁶ Department of Oncology, Oslo University Hospital, Oslo, Norway.
⁷ Department of Radiation Biology, Oslo University Hospital, Oslo, Norway; Department of Physics, University of Oslo, Oslo, Norway. Electronic address: Heidi.Lyng@rr-research.no.

PMID: 38556173
DOI: 10.1016/j.radonc.2024.110263

Abstract

Background and purpose: Improvements in treatment outcome for patients with locally advanced cervical cancer (LACC) require a better classification of patients according to their risk of recurrence. We investigated whether an imaging-based approach, combining pretreatment hypoxia and tumor response during therapy, could improve risk classification.

Material and methods: Ninety-three LACC patients with T2-weigthed (T2W)-, dynamic contrast enhanced (DCE)- and diffusion weighted (DW)-magnetic resonance (MR) images acquired before treatment, and T2W- and, for 64 patients, DW-MR images, acquired at brachytherapy, were collected. Pretreatment hypoxic fraction (HF_pre) was determined from DCE- and DW-MR images using the consumption and supply-based hypoxia (CSH)-imaging method. Volume regression at brachytherapy was assessed from T2W-MR images and combined with HF_pre. In 17 patients with adequate DW-MR images at brachytherapy, the apparent diffusion coefficient (ADC), reflecting tumor cell density, was calculated. Change in ADC during therapy was combined with volume regression yielding functional regression as explorative response measure. Endpoint was disease free survival (DFS).

Results: HF_pre was the strongest predictor of DFS, but a significant correlation with outcome was found also for volume regression. The combination of HF_pre and volume regression showed a stronger association with DFS than HF_pre alone. Patients with disease recurrence were selected to either the intermediate- or high-risk group with a 100 % accuracy. Functional regression showed a stronger correlation to HF_pre than volume regression.

Conclusion: The combination of pretreatment hypoxia and volume regression at brachytherapy improved patient risk classification. Integration of ADC with volume regression showed promise as a new tumor response parameter.